未登录

J

Jennifer Sheng

incyte corporation

H指数:12

被引数:635

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

De-risking Biopharma Asset Acquisition: Towards a Quantitative Framework for Strategic Decision-making

生物制药资产收购的风险规避：迈向战略决策的定量框架

The AAPS Journal

IF0

2026-05-060

OAAI

Advancing drug development with Fit-for-Purpose modeling informed approaches

以基于目的建模方法推动药物研发

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

IF2.8

2025-09-150

OAAI

Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease

阿萨替利单抗在慢性移植物抗宿主病患者中的暴露-反应关系

Clinical Pharmacology & Therapeutics

IF5.5

2025-06-190

OA

Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with Ipilimumab

基于模型的尼鲁单抗单药治疗及联合伊匹单抗的免疫原性评估

IF3.7

2025-04-250

PRE

Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host Disease

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-12-200

OAAI

Machine Learning in Predicting Longitudinal Platelet Counts: Applications in Dose Optimization

机器学习在预测纵向血小板计数中的应用：剂量优化的应用

IF23.1

2024-11-050

PRE

Real-world outcomes of diffuse large B cell lymphoma treated with R-CHOP(-like) therapy in an Asian multi-ethnic population

ANNALS OF ONCOLOGY

IF65.4

2023-11-010

PRE

Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2022-06-112

OAAI

Evaluation of flat dosing for nivolumab (NIVO) plus ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)

ANNALS OF ONCOLOGY

IF65.4

2020-12-010

OAAI

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2020-07-2222

OAAI

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2019-12-0122

OAAI

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2019-12-0125

OA

Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2019-02-257

PREAI

Challenges and Opportunities With Oncology Drug Development in China

中国肿瘤药物发展的挑战与机遇

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2018-03-0823

PREAI

An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab

IF3.7

2017-01-099

PREAI

Application of Physiologically Based Absorption Modeling to Formulation Development of a Low Solubility, Low Permeability Weak Base: Mechanistic Investigation of Food Effect

AAPS PHARMSCITECH

IF4

2014-01-1736

OA

Utility of Physiologically Based Modeling and Preclinical In Vitro/In Vivo Data to Mitigate Positive Food Effect in a BCS Class 2 Compound

AAPS PHARMSCITECH

IF4

2013-08-1725

OA